Abstract

Objectives The NUTRIC (nutrition risk in the critically ill) score and the modified NUTRIC score are two scoring systems that show the nutritional risk status and severity of acute disease of patients. The only difference between them is the examination of interleukin-6 (IL-6) level. The aim of this study was to investigate whether or not the NUTRIC score is superior to the mNUTRIC score in the prediction of mortality of patients with COVID-19 followed up in the Intensive Care Unit (ICU). Material and Method. This retrospective study included 322 patients followed up in ICU with a diagnosis of COVID-19. A record was made of demographic data, laboratory values, clinical results, and mortality status. All the data of the patients were compared between high and low variations of the NUTRIC score and the mNUTRIC score. Results A high NUTRIC score was determined in 62 patients and a high mNUTRIC score in 86 patients. The need for invasive mechanical ventilation, the use of vasopressors in ICU, the development of acute kidney injury, and mortality rates were statistically significantly higher in the patients with high NUTRIC and high mNUTRIC scores than in those with low scores (p = 0.0001 for all). The AUC values were 0.791 for high NUTRIC score and 0.786 for high mNUTRIC score (p = 0.0001 for both). No statistically significant difference was determined between the two scoring systems. Conclusion Although the NUTRIC score was seen to be superior to the mNUTRIC score, no statistically significant difference was determined. Therefore, when IL-6 cannot be examined, the mNUTRIC score can be considered safe and effective for the prediction of mortality in COVID-19 patients.

Highlights

  • At the end of December 2019, a new coronavirus (2019nCoV, SARS-CoV-2) was identified in a case series of pneumonia with rapid person-to-person infection in the city of Wuhan, Hubei Province, China [1]

  • Study Population and Protocol. is retrospective study included the data of patients aged 18 years who were followed up in three COVID-19 Intensive Care Unit (ICU) in Ankara City Hospital between June 1st and November 1st, 2020. e diagnosis of COVID-19 was made from a positive reverse transcriptase polymerase chain reaction test (RT-PCR) and/or thorax computed tomography (CT) findings consistent with COVID-19. e patients followed up in ICU were severe pneumonia cases and critical patients

  • As there is still no safe and effective treatment for COVID-19, which can lead to a severe clinical status, many studies continue to be conducted on the risk factors of the disease, clinical outcomes, disease course, morbidity, and mortality

Read more

Summary

Introduction

At the end of December 2019, a new coronavirus (2019nCoV, SARS-CoV-2) was identified in a case series of pneumonia with rapid person-to-person infection in the city of Wuhan, Hubei Province, China [1]. In February 2020, this pneumonia was named coronavirus disease 2019 (COVID19) by the World Health Organization (WHO) [2]. E virus is spread through aerosol droplets in COVID19 infection and most patients can have a mild disease course with symptoms such as fever, listlessness, muscle and joint pains, loss of appetite, headache, nausea, vomiting, loss of taste and smell, and cough [5]. Ese two patient groups are followed up in the Intensive Care Unit (ICU). This classification provides important guidance about disease prognosis and mortality, the length of hospital stay of critical patients and those with severe pneumonia increases morbidity, mortality, and hospital costs [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call